Document Detail

Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation.
MedLine Citation:
PMID:  12107099     Owner:  NLM     Status:  MEDLINE    
Hyperhomocysteinemia (HHcy) is a newly recognized risk factor for myocardial infarction, however, the effect of HHcy on endothelium-dependent flow-induced dilation of coronary arteries is not known. Thus, changes in diameter of small intramural coronary arteries (diameter, approximately 145 microm) isolated from control rats and rats with methionine diet-induced HHcy were investigated by videomicroscopy. Increases in intraluminal flow (from 0 to 40 microl/min) elicited dilations of control vessels (maximum, 25 +/- 2 microm), responses that were absent in HHcy arteries. The nitric oxide (NO) synthase inhibitor L-NAME inhibited flow-induced dilation of control coronaries, whereas it had no effect on responses of HHcy arteries. Dilations of control and HHcy arteries to the NO donor sodium nitroprusside were not different. Responses to flow in HHcy coronary arteries were unaffected by administration of L-arginine or the prostaglandin H(2)/thromboxane A(2) receptor antagonist SQ 29,548. However, in the presence of superoxide dismutase (plus catalase) or the superoxide scavenger Tiron increases in flow elicited L-NAME-sensitive dilations of HHcy coronaries (maximum, 18 +/- 5 microm). Also, superoxide dismutase significantly reduced the enhanced superoxide production of HHcy coronaries (measured by the lucigenin chemiluminescence method). Single vessel Western blotting showed an increased tyrosine nitrosation (a stable biomarker of tissue peroxynitrite formation) in HHcy coronaries. Also, extensive prevalence of 3-nitrotyrosine immunoreactivity was observed in HHcy coronaries that was confined primarily to the subendothelial layers of smooth muscle. We propose that in HHcy an increased level of superoxide scavenges NO forming peroxynitrite, which increases protein nitrosation. The reduced bioavailability of NO impairs flow-induced dilations of coronary arteries, which may contribute to the development of coronary atherosclerosis and ischemic heart disease.
Zoltan Ungvari; Anna Csiszar; Zsolt Bagi; Akos Koller
Related Documents :
16466579 - Value of adenosine infusion for infarct size determination using real-time myocardial c...
10536679 - The isoprostane, 8-epi-pgf2 alpha, is accumulated in coronary arteries isolated from pa...
22908919 - Pacing in sinus node disease to prevent atrial fibrillation.
22516069 - Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather th...
1982609 - Alpha 2-adrenergic coronary constriction in ischemic myocardium during exercise.
1653539 - Time course of endothelial dysfunction and myocardial injury during coronary arterial o...
10373219 - Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production i...
12716649 - An easy and safe way of left ventriculotomy closure in patients with left ventricle thr...
23557229 - Fast diastolic swinging motion of the mitral valve as a clinical marker of familial hyp...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of pathology     Volume:  161     ISSN:  0002-9440     ISO Abbreviation:  Am. J. Pathol.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-10     Completed Date:  2002-08-06     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  0370502     Medline TA:  Am J Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  145-53     Citation Subset:  AIM; IM    
Department of Pathophysiology, Semmelweis University, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blotting, Western
Coronary Circulation / drug effects,  physiology*
Coronary Vessels / metabolism
Enzyme Inhibitors / pharmacology
Hyperhomocysteinemia / pathology,  physiopathology*
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide / physiology*
Peroxynitrous Acid / biosynthesis,  pharmacology
Rats, Wistar
Superoxides / metabolism
Tyrosine / analogs & derivatives*,  metabolism
Grant Support
Reg. No./Substance:
0/Enzyme Inhibitors; 10102-43-9/Nitric Oxide; 11062-77-4/Superoxides; 14691-52-2/Peroxynitrous Acid; 3604-79-3/3-nitrotyrosine; 50903-99-6/NG-Nitroarginine Methyl Ester; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endot...
Next Document:  STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers.